Syntopix to research biofilms for Beiersdorf
To develop and validate screening assays to improve topical antimicrobial efficacy
Syntopix Group, a UK topical antimicrobial innovations specialist, has signed a research agreement with Beiersdorf to develop new lab-based assays to help examine the effective delivery of active ingredients in order to maximise their bioavailability on skin.
Beiersdorf, which owns skin care brands such as Nivea and La Prairie, will pay Syntopix an undisclosed research contract fee to establish and validate screening assays to improve topical antimicrobial efficacy.
Stephen Jones, chief executive of Syntopix, said: “Syntopix’s wider work on skin disorders and oral health has given our team a deep understanding of factors affecting the topical efficacy of antimicrobials. Our assays will facilitate the development of new antimicrobial strategies to address this important challenge.”
Heiner Max, head of research Personal Care at Beiersdorf added: “Beiersdorf’s expertise is closely aligned with that of Syntopix. Together we are in a strong position to work towards developing unique and effective products.”
Syntopix was founded in 2003 as a spin-out from the University of Leeds by Dr Jon Cove and Dr Anne Eady, experts in skin microbiology.
The firm develops innovative compounds which have clinical efficacy and proven benefits for the treatment of acne, gingivitis and body odour.